1. Inicio
  2. Proyectos y Estudios
  3. “A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients.

“A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients.

Datos básicos

ENSAYO CLÍNICO EMN39 HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE Año de incio: 2025

Documentos

  • No hay documentos

Participantes

Ver todos los Investigadores

Grupos

Financiadores - Promotores

EUROPEAN MYELOMA NETWORK (EMN) C/O PAREXEL INTERNATIONAL (IRL)

Cita

Compartir